Total Payments
$235.81
2023 Payments
$13.60
Companies
8
Transactions
11
Medicare Patients
8,293
Medicare Billing
$1.3M
Payment Breakdown by Category
Food & Beverage$210.93 (89.4%)
Education$24.88 (10.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $210.93 | 6 | 89.4% |
| Education | $24.88 | 5 | 10.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bard Peripheral Vascular, Inc. | $134.85 | 1 | $0 (2020) |
| Vifor Pharma, Inc. | $26.55 | 2 | $0 (2022) |
| Lundbeck LLC | $17.62 | 1 | $0 (2017) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $16.53 | 1 | $0 (2019) |
| Daiichi Sankyo Inc. | $15.38 | 1 | $0 (2022) |
| Calliditas Therapeutics US Inc. | $13.60 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $13.60 | 1 | Calliditas Therapeutics US Inc. ($13.60) |
| 2022 | $29.35 | 2 | Daiichi Sankyo Inc. ($15.38) |
| 2021 | $16.40 | 2 | Vifor Pharma, Inc. ($12.58) |
| 2020 | $138.67 | 2 | Bard Peripheral Vascular, Inc. ($134.85) |
| 2019 | $20.17 | 3 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($16.53) |
| 2017 | $17.62 | 1 | Lundbeck LLC ($17.62) |
All Payment Transactions
11 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2023 | Calliditas Therapeutics US Inc. | TARPEYO (Drug) | Education | Cash or cash equivalent | $13.60 | General |
| Category: Nephrology | ||||||
| 03/08/2022 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $15.38 | General |
| Category: Iron Deficiency Anemia | ||||||
| 01/07/2022 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $13.97 | General |
| Category: Hyperkalemia | ||||||
| 06/09/2021 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $12.58 | General |
| Category: Hyperkalemia | ||||||
| 03/11/2021 | Travere Therapeutics, Inc. | Thiola (Drug) | Education | In-kind items and services | $3.82 | General |
| Category: Kidney Stones | ||||||
| 05/21/2020 | Travere Therapeutics, Inc. | (815) Thiola (Drug) | Education | In-kind items and services | $3.82 | General |
| Category: Kidney Stones | ||||||
| 01/06/2020 | Bard Peripheral Vascular, Inc. | — | Food and Beverage | In-kind items and services | $134.85 | General |
| Category: BD Interventional - Peripheral Intervention | ||||||
| 08/07/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $16.53 | General |
| Category: NEPHROLOGY | ||||||
| 05/30/2019 | Retrophin, Inc. | (815) Thiola (Drug) | Education | In-kind items and services | $2.33 | General |
| Category: Kidney Stones | ||||||
| 05/30/2019 | Retrophin, Inc. | (815) Thiola (Drug) | Education | In-kind items and services | $1.31 | General |
| Category: Kidney Stones | ||||||
| 11/30/2017 | Lundbeck LLC | NORTHERA (Drug) | Food and Beverage | Cash or cash equivalent | $17.62 | General |
| Category: NEUROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 36 | 1,635 | 5,804 | $988,300 | $295,118 |
| 2022 | 40 | 1,934 | 5,035 | $1.1M | $342,251 |
| 2021 | 48 | 2,427 | 5,800 | $1.3M | $384,325 |
| 2020 | 49 | 2,297 | 17,467 | $1.3M | $328,190 |
Total Patients
8,293
Total Services
34,106
Medicare Billing
$1.3M
Procedure Codes
173
All Medicare Procedures & Services
173 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| G0277 | Hyperbaric oxygen under pressure, full body chamber, per 30 minute interval | Office | 2023 | 19 | 646 | $226,746 | $86,060 | 38.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 208 | 513 | $180,063 | $45,243 | 25.1% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 50 | 134 | $123,548 | $36,111 | 29.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 92 | 430 | $101,480 | $26,432 | 26.0% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 11 | 840 | $49,980 | $15,627 | 31.3% |
| 99183 | Management of oxygen chamber therapy | Office | 2023 | 19 | 163 | $58,191 | $13,327 | 22.9% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 33 | 51 | $39,525 | $11,238 | 28.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 87 | 87 | $32,712 | $11,027 | 33.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 54 | 74 | $34,780 | $10,030 | 28.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 54 | 65 | $42,575 | $8,795 | 20.7% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 11 | 722 | $20,044 | $4,366 | 21.8% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 135 | 303 | $8,181 | $3,130 | 38.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 152 | 407 | $6,299 | $3,023 | 48.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 26 | 32 | $10,784 | $2,971 | 27.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 42 | 50 | $11,450 | $2,385 | 20.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 132 | 300 | $6,000 | $2,283 | 38.1% |
| 83970 | Parathormone (parathyroid hormone) level | Office | 2023 | 23 | 51 | $5,304 | $2,063 | 38.9% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 55 | 92 | $3,956 | $1,514 | 38.3% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 20 | 20 | $3,160 | $1,439 | 45.5% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 64 | 100 | $3,400 | $1,312 | 38.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 35 | 107 | $5,778 | $1,109 | 19.2% |
| 82306 | Vitamin d-3 level | Office | 2023 | 22 | 37 | $2,775 | $1,073 | 38.7% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 25 | 25 | $1,650 | $755.75 | 45.8% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 29 | 50 | $1,250 | $476.00 | 38.1% |
| 80069 | Kidney function blood test panel | Office | 2023 | 11 | 52 | $1,144 | $442.52 | 38.7% |
About Dr. Robert Pinnick, MD
Dr. Robert Pinnick, MD is a Specialist healthcare provider based in Bend, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1386691269.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Pinnick, MD has received a total of $235.81 in payments from pharmaceutical and medical device companies, with $13.60 received in 2023. These payments were reported across 11 transactions from 8 companies. The most common payment nature is "Food and Beverage" ($210.93).
As a Medicare-enrolled provider, Pinnick has provided services to 8,293 Medicare beneficiaries, totaling 34,106 services with total Medicare billing of $1.3M. Data is available for 4 years (2020–2023), covering 173 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Other Specialties Internal Medicine, Undersea and Hyperbaric Medicine
- Location Bend, OR
- Active Since 05/27/2006
- Last Updated 04/08/2021
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1386691269
Products in Payments
- Veltassa (Drug) $26.55
- NORTHERA (Drug) $17.62
- JYNARQUE (Drug) $16.53
- INJECTAFER (Drug) $15.38
- TARPEYO (Drug) $13.60
- (815) Thiola (Drug) $7.46
- Thiola (Drug) $3.82
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Bend
Dr. Andrew Jones, Md, MD
Specialist — Payments: $301,437
Specialist $301,437
Dr. Timothy Beard, M.d,, M.D,
Specialist — Payments: $200,366
Specialist $200,366
Stephen Kornfeld, Md, MD
Specialist — Payments: $52,446
Specialist $52,446
Dr. Anthony Hadden, M.d, M.D
Specialist — Payments: $45,603
Specialist $45,603
Michael Mastrangelo, M.d, M.D
Specialist — Payments: $16,076
Specialist $16,076
Robert Boone, Md, MD
Specialist — Payments: $13,624
Specialist $13,624